dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade Federal do Rio de Janeiro (UFRJ)
dc.date.accessioned2014-05-27T11:21:06Z
dc.date.accessioned2022-10-05T17:53:09Z
dc.date.available2014-05-27T11:21:06Z
dc.date.available2022-10-05T17:53:09Z
dc.date.created2014-05-27T11:21:06Z
dc.date.issued2004-07-01
dc.identifierQuimica Nova, v. 27, n. 4, p. 655-660, 2004.
dc.identifier0100-4042
dc.identifierhttp://hdl.handle.net/11449/67779
dc.identifier10.1590/S0100-40422004000400021
dc.identifierS0100-40422004000400021
dc.identifierWOS:000223108900021
dc.identifier2-s2.0-15044356788
dc.identifier2-s2.0-15044356788.pdf
dc.identifier4484083685251673
dc.identifier1308042794786872
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3917395
dc.description.abstractAlzheimer's disease (AD) is a progressive neurodegenerative pathology with severe economic and social impact. There is currently no cure, although cholinesterase inhibitors provide effective temporary relief of symptoms in some patients. Nowadays drug research and development are based on the cholinergic hypothesis that supports the cognition improvement by regulation of the synthesis and release of acetylcholine in the brain. There are only four commercial medicines approved for treatment of AD and natural products have played an important role in the research for new acetylcholinesterase inhibitors.
dc.languagepor
dc.relationQuímica Nova
dc.relation0.646
dc.relation0,255
dc.rightsAcesso aberto
dc.sourceScopus
dc.subjectAcetylcholinesterase
dc.subjectAlzheimer's disease
dc.subjectNatural products
dc.subject11 hydroxygalantamine
dc.subject9 o norgalantamine
dc.subjectacetylcholine
dc.subjectcholinesterase inhibitor
dc.subjectdonepezil
dc.subjectgalantamine
dc.subjectGinkgo biloba extract
dc.subjectnatural product
dc.subjectrivastigmine
dc.subjecttacrine
dc.subjectunclassified drug
dc.subjectacetylcholine release
dc.subjectAlzheimer disease
dc.subjectbrain function
dc.subjectcholinergic activity
dc.subjectcognition
dc.subjectconference paper
dc.subjectdegenerative disease
dc.subjectdrug efficacy
dc.subjectdrug indication
dc.subjectdrug synthesis
dc.subjecteconomic aspect
dc.subjecthypothesis
dc.subjectneuropathology
dc.subjectregulatory mechanism
dc.subjectsocial aspect
dc.titleProdutos naturais como candidatos a fármacos úteis no tratamento do mal de Alzheimer
dc.typeTrabalho apresentado em evento


Este ítem pertenece a la siguiente institución